DACARBAZINE Side Effects

6999084-6 | Hypokalaemia, Hypotension, Meningitis Aseptic, Nausea, Pyrexia
on Sep 13, 2010 Male patient from UNITED STATES , 68 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: hypokalaemia, hypotension, meningitis aseptic, nausea (What is nausea?), pyrexia. Dacarbazine dosage: Received '4 Courses' Nos. During the same period patient was treated with IPILIMUMAB (Received '7 Courses' Nos) (View Ipilimumab Review and Ipilimumab Label ), CORTEF (View Cortef Review and Cortef Label ), TESSALON (View Tessalon Review and Tessalon Label ), PROTONIX (View Protonix Review and Protonix Label ), KENALOG (View Kenalog Review and Kenalog Label ), BENICAR (View Benicar Review and Benicar Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6999082-2 | Anaemia, Dehydration, Thrombocytopenia
Patient was taking Dacarbazine (View Usage). Patient had the following side effects: anaemia, dehydration, thrombocytopenia on Sep 13, 2010 from UNITED STATES Additional patient health information: Male patient , 55 years of age, was diagnosed with metastatic malignant melanoma and. Dacarbazine dosage: Unit Dose: 220 Mg/m2. During the same period patient was treated with CARMUSTINE (Unit Dose: 50 Mg/m2) (View Carmustine Review and Carmustine Label ), CISPLATIN (Unit Dose: 25 Mg/m2) (View Cisplatin Review and Cisplatin Label ), XL281 (BMS908662 INVESTIGATIONAL) (View Xl281 (bms908662-investigational) Review and Xl281 (bms908662-investigational) Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), MANNITOL (View Mannitol Review and Mannitol Label ), NAPROSYN (View Naprosyn Review and Naprosyn Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

6984405-0 | Asthenia, Neutropenia, Septic Shock
Adverse event was reported on Sep 01, 2010 by a Female patient taking Dacarbazine (View Usage) (Dosage: Days 1-5 Of Cycle One) was diagnosed with metastatic malignant melanoma, sepsis (What is sepsis?) and. Location: KOREA, REPUBLIC OF , 46 years of age, After Dacarbazine was administered, patient had the following side effects: asthenia, neutropenia, septic shock. During the same period patient was treated with VINBLASTINE (Days 1-3 Of Cycle One) (View Vinblastine Review and Vinblastine Label ), CISPLATIN (Days 1-5 Of Cycle One) (View Cisplatin Review and Cisplatin Label ), CYCLOPHOSPHAMIDE (D1 C1) (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (D1 And 5 C1) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (D1 C1) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

6984403-7 | Lymphopenia, Sarcoidosis
on Sep 06, 2010 Female patient from UNITED STATES , 49 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: lymphopenia, sarcoidosis. Dacarbazine dosage: Six Cycles. During the same period patient was treated with DOXORUBICIN HCL (Six Cycles) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), BLEOMYCIN SULFATE (Six Cycles) (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE (Six Cycles) (View Vinblastine Review and Vinblastine Label ).


6970534-4 | Anaemia, Dehydration, Thrombocytopenia
on Aug 30, 2010 Male patient from UNITED STATES , 55 years of age, was diagnosed with metastatic malignant melanoma and was treated with Dacarbazine (View Usage). Patient had the following side effects: anaemia, dehydration, thrombocytopenia. Dacarbazine dosage: Unit Dose: 220 Mg/m2. During the same period patient was treated with CARMUSTINE (Unit Dose: 50 Mg/m2) (View Carmustine Review and Carmustine Label ), CISPLATIN (Unit Dose: 25 Mg/m2) (View Cisplatin Review and Cisplatin Label ), XL281 (BMS908662 INVESTIGATIONAL) (View Xl281 (bms908662-investigational) Review and Xl281 (bms908662-investigational) Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), MANNITOL (View Mannitol Review and Mannitol Label ), NAPROSYN (View Naprosyn Review and Naprosyn Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

6944639-8 | Fatigue, Hypertension
Patient was taking Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: fatigue, hypertension on Aug 14, 2010 from FINLAND Additional patient health information: Female patient , 47 years of age, was diagnosed with metastatic malignant melanoma and. Dacarbazine dosage: As Used: 200 Mg/m2. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (View Roferon-a Review and Roferon-a Label ).

6944636-2 | Fatigue, Hypertension, Pyrexia
Adverse event was reported on Aug 14, 2010 by a Female patient taking Dacarbazine (View Usage) (Dosage: As Used: 200 Mg/m2) was diagnosed with metastatic malignant melanoma and. Location: FINLAND , 62 years of age, Patient experienced the following unwanted or unexpected effects: fatigue, hypertension, pyrexia. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (View Roferon-a Review and Roferon-a Label ).

6944635-0 | Epistaxis, Hypertension
on Aug 14, 2010 Male patient from FINLAND , 66 years of age, was diagnosed with metastatic malignant melanoma and was treated with Dacarbazine (View Usage). Patient had the following side effects: epistaxis, hypertension. Dacarbazine dosage: As Used: 200 Mg/m2. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (View Roferon-a Review and Roferon-a Label ).

6938420-3 | Chest Discomfort, Dyspnoea
on Jun 03, 2010 Female patient from SOUTH AFRICA , 42 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: chest discomfort, dyspnoea. Dacarbazine dosage: . During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ).

6938419-7 | Fatigue, Hypertensive Crisis
Patient was taking Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: fatigue, hypertensive crisis on Aug 14, 2010 from FINLAND Additional patient health information: Male patient , 60 years of age, was diagnosed with metastatic malignant melanoma and. Dacarbazine dosage: As Used: 200 Mg/m2. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (View Roferon-a Review and Roferon-a Label ).

6938418-5 | Cerebral Haemorrhage, Dysphonia, Hypertension
Adverse event was reported on Aug 14, 2010 by a Male patient taking Dacarbazine (View Usage) (Dosage: Total Daily Dose: 200 Mg/m2) was diagnosed with metastatic malignant melanoma and. Location: FINLAND , 69 years of age, Patient had the following side effects: cerebral haemorrhage, dysphonia, hypertension. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (From Day 15 Of Cycle 1 Onwards) (View Roferon-a Review and Roferon-a Label ).

6936745-9 | Cerebral Haemorrhage, Dysphonia, Hypertension
on Aug 14, 2010 Male patient from FINLAND , 69 years of age, was diagnosed with metastatic malignant melanoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: cerebral haemorrhage, dysphonia, hypertension. Dacarbazine dosage: Total Daily Dose: 200 Mg/m2. During the same period patient was treated with BEVACIZUMAB (Cycles, On Treatment Day 1 And 15 Every 28 Days) (View Bevacizumab Review and Bevacizumab Label ), ROFERON A (From Day 15 Of Cycle 1 Onwards) (View Roferon-a Review and Roferon-a Label ).

6929077-6 | Anaphylactic Shock, Blood Pressure Systolic Decreased, Body Temperature Increased, Chills, Continuous Haemodiafiltration, Cytokine Storm, Hyperkalaemia, Hypotension, Infusion Site Pain
on Jul 30, 2010 Male patient from JAPAN , 36 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic shock, blood pressure systolic decreased, body temperature increased, chills, continuous haemodiafiltration, cytokine storm, hyperkalaemia, hypotension, infusion site pain. Dacarbazine dosage: (375 Mg/m2, 2 Hr Infusion) Intravenous Drip. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINBLASTINE (VINBLASTINE) (VINBLASTINE) (View Vinblastine (vinblastine) (vinblastine) Review and Vinblastine (vinblastine) (vinblastine) Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ).

6894337-4 | Chest Discomfort, Dyspnoea
Patient was taking Dacarbazine (View Usage). Patient had the following side effects: chest discomfort, dyspnoea on Jun 03, 2010 from SOUTH AFRICA Additional patient health information: Female patient , 42 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Dacarbazine dosage: . During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ).

6768190-3 | Gastrointestinal Perforation
Adverse event was reported on Jun 03, 2010 by a Male patient taking Dacarbazine (View Usage) (Dosage: 1560mg (800mg/m2)iv/once) was diagnosed with metastatic malignant melanoma and. Location: , 52 years of age, After Dacarbazine was administered, patient had the following side effects: gastrointestinal perforation. Patient was hospitalized.

6760406-2 | Dyspnoea Exertional, Gastrointestinal Perforation, Leukocytosis, Thrombocytosis
on May 20, 2010 Male patient from NETHERLANDS , 52 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea exertional, gastrointestinal perforation, leukocytosis, thrombocytosis. Dacarbazine dosage: 1560 Mg, Once, Intravenous. Patient was hospitalized.

6753588-X | Skin Infection, Staphylococcal Bacteraemia
on May 17, 2010 Female patient from UNITED KINGDOM , 50 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient had the following side effects: skin infection, staphylococcal bacteraemia. Dacarbazine dosage: 652.5mg Milligram (s) Intraveous. During the same period patient was treated with DOXORUBICIN HCL (43.5mg Milligram (s) Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), NYSTATIN (View Nystatin Review and Nystatin Label ). Patient was hospitalized.

6725656-X | Hypotension, Mental Status Changes, Nausea, Pyrexia
Patient was taking Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: hypotension, mental status changes, nausea (What is nausea?), pyrexia on May 10, 2010 from UNITED STATES Additional patient health information: Male patient , 68 years of age, was diagnosed with malignant melanoma and. Dacarbazine dosage: Received '4 Courses' Nos. During the same period patient was treated with IPILIMUMAB (Received '7 Courses' Nos) (View Ipilimumab Review and Ipilimumab Label ), CORTEF (View Cortef Review and Cortef Label ), TESSALON (View Tessalon Review and Tessalon Label ), PROTONIX (View Protonix Review and Protonix Label ), KENALOG (View Kenalog Review and Kenalog Label ), BENICAR (View Benicar Review and Benicar Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6709345-3 | Convulsion, Cytokine Storm, Loss Of Consciousness, Pyrexia, Tumour Lysis Syndrome
Adverse event was reported on Apr 27, 2010 by a Male patient taking Dacarbazine (View Usage) (Dosage: 100 Mg) was diagnosed with hodgkin's disease (What is hodgkin's disease?), prophylaxis of nausea and vomiting and. Location: JAPAN , 36 years of age, weighting 183.0 lb, Patient experienced the following unwanted or unexpected effects: convulsion, cytokine storm, loss of consciousness, pyrexia, tumour lysis syndrome. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ).

6697009-4 | Diffuse Large B-cell Lymphoma, Spinal Cord Compression, Treatment Related Secondary Malignancy, Tumour Compression
on Apr 17, 2010 Female patient from SINGAPORE , 73 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient had the following side effects: diffuse large b-cell lymphoma, spinal cord compression, treatment related secondary malignancy, tumour compression. Dacarbazine dosage: Six Cycles. During the same period patient was treated with ADRIAMYCIN PFS (Six Cycles) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN (Six Cycles) (View Bleomycin Review and Bleomycin Label ), VINBLASTINE SULFATE (Six Cycles) (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ).

6697001-X | Acute Myeloid Leukaemia, Haemorrhage Intracranial
on Apr 17, 2010 Female patient from SINGAPORE , 56 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: acute myeloid leukaemia, haemorrhage intracranial. Dacarbazine dosage: Six Cycles. During the same period patient was treated with ADRIAMYCIN PFS (Six Cycles) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN (Six Cycles) (View Bleomycin Review and Bleomycin Label ), VINBLASTINE SULFATE (Six Cycles) (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ).

6675240-1 | Acute Lymphocytic Leukaemia
Patient was taking Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia on Feb 27, 2010 from UNITED STATES Additional patient health information: Male patient , 74 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Dacarbazine dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6675233-4 | Acute Lymphocytic Leukaemia
Adverse event was reported on Feb 27, 2010 by a Male patient taking Dacarbazine (View Usage) (Dosage: ) was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Location: UNITED STATES , 34 years of age, Patient had the following side effects: acute lymphocytic leukaemia. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6656141-1 | Renal Failure Acute, Tumour Lysis Syndrome
on Mar 16, 2010 Male patient from CHINA , 44 years of age, was diagnosed with sarcoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: renal failure acute, tumour lysis syndrome. Dacarbazine dosage: 400 Mg/me2 On Day 1 Through 3 Per Cycle, 3 Cycles In Total. During the same period patient was treated with CISPLATIN (30 Mg/me2 On Day 1 To 3 Of First Cycle) (View Cisplatin Review and Cisplatin Label ), ADRIAMYCIN PFS (30 Mg/me2 On Days 1 And 3 Per Cycle, 3 Cycles In Total) (View Adriamycin Pfs Review and Adriamycin Pfs Label ). Patient was hospitalized.

6648560-4 | Neurotoxicity
on Mar 10, 2010 Male patient from ITALY , 51 years of age, was diagnosed with medulloblastoma and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: neurotoxicity. Dacarbazine dosage: For 6 Cycles. During the same period patient was treated with ETOPOSIDE (For 6 Cycles) (View Etoposide Review and Etoposide Label ), CISPLATIN (For 6 Cycles) (View Cisplatin Review and Cisplatin Label ).

6648511-2 | Gastrointestinal Perforation
Patient was taking Dacarbazine (View Usage). Patient had the following side effects: gastrointestinal perforation on Mar 10, 2010 from NETHERLANDS Additional patient health information: Male patient , 52 years of age, was diagnosed with metastatic malignant melanoma and. Dacarbazine dosage: 800 Mg/m2.

6631822-4 | Acute Lymphocytic Leukaemia
Adverse event was reported on Feb 27, 2010 by a Male patient taking Dacarbazine (View Usage) (Dosage: ) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: UNITED STATES , 74 years of age, After Dacarbazine was administered, patient had the following side effects: acute lymphocytic leukaemia. During the same period patient was treated with DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6631808-X | Acute Lymphocytic Leukaemia
on Feb 27, 2010 Male patient from UNITED STATES , 34 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia. Dacarbazine dosage: . During the same period patient was treated with DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), VINBLASTINE (View Vinblastine Review and Vinblastine Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6577308-7 | Metastatic Malignant Melanoma
on Jan 29, 2010 Male patient from UNITED STATES , 43 years of age, was diagnosed with metastatic malignant melanoma and was treated with Dacarbazine (View Usage). Patient had the following side effects: metastatic malignant melanoma. Dacarbazine dosage: . During the same period patient was treated with FOTEMUSTINE (View Fotemustine Review and Fotemustine Label ), TEMODAL (View Temodal Review and Temodal Label ).

6546894-5 | Depression, Senile Dementia
Patient was taking Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: depression (What is depression?), senile dementia on Jan 07, 2010 from JAPAN Additional patient health information: Male patient , 39 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Dacarbazine dosage: 4 Courses, 1-month Interval, Over A Period Of 3 Months. During the same period patient was treated with ADRIAMYCIN PFS (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN SULFATE (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Vinblastine Review and Vinblastine Label ).

6546531-X | Fatigue
Adverse event was reported on Dec 22, 2009 by a Male patient taking Dacarbazine (View Usage) (Dosage: ) . Location: UNITED STATES , 76 years of age, Patient experienced the following unwanted or unexpected effects: fatigue.

6543666-2 | Depression, Senile Dementia
on Jan 07, 2010 Male patient from JAPAN , 39 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Dacarbazine (View Usage). Patient had the following side effects: depression (What is depression?), senile dementia. Dacarbazine dosage: 4 Courses, 1-month Interval, Over A Period Of 3 Months. During the same period patient was treated with ADRIAMYCIN PFS (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN SULFATE (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE (4 Courses, 1-month Interval, Over A Period Of 3 Months) (View Vinblastine Review and Vinblastine Label ).

6527354-4 | Anaemia, Fatigue, Malignant Melanoma
on Dec 22, 2009 Male patient from UNITED STATES , 65 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: anaemia, fatigue, malignant melanoma. Dacarbazine dosage: . Patient was hospitalized.

6523046-6 | Anaemia, Fatigue, Malignant Melanoma
Patient was taking Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, fatigue, malignant melanoma on Dec 22, 2009 from UNITED STATES Additional patient health information: Male patient , 65 years of age, was diagnosed with malignant melanoma and. Dacarbazine dosage: . Patient was hospitalized.

6400997-4 | Blood Creatine Increased, Blood Urea Increased, Dyspnoea, Fluid Overload, Hepatic Enzyme Increased, Malignant Neoplasm Progression, Pleural Effusion, Somnolence
Adverse event was reported on Oct 13, 2009 by a Male patient taking Dacarbazine (View Usage) (Dosage: 1000mg/m2 Q 3 Wk) was diagnosed with malignant melanoma and. Location: UNITED STATES , weighting 177.3 lb, Patient had the following side effects: blood creatine increased, blood urea increased, dyspnoea, fluid overload, hepatic enzyme increased, malignant neoplasm progression, pleural effusion, somnolence. During the same period patient was treated with DASATINIB (100mg Qd Day 2-19) (View Dasatinib Review and Dasatinib Label ), METAPROLOL (View Metaprolol Review and Metaprolol Label ), ZOCOR (View Zocor Review and Zocor Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), CALCIUM (View Calcium Review and Calcium Label ), GLUCOSAMINE (View Glucosamine Review and Glucosamine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6386423-2 | Haemothorax, Pleural Effusion, Pleural Neoplasm
on Sep 30, 2009 Male patient from UNITED STATES , weighting 177.3 lb, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: haemothorax, pleural effusion, pleural neoplasm. Dacarbazine dosage: 1000mg/m2 Q 3 Wk. During the same period patient was treated with DASTINIB (100mg Qd Day 2-19) (View Dastinib Review and Dastinib Label ), METAPROLOL (View Metaprolol Review and Metaprolol Label ), ZOCOR (View Zocor Review and Zocor Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), CALCIUM (View Calcium Review and Calcium Label ), GLUCOSAMINE (View Glucosamine Review and Glucosamine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), VITAMINS (View Vitamins Review and Vitamins Label ). Patient was hospitalized.

6386421-9 | Condition Aggravated, Fluid Overload, Pleural Effusion
on Sep 30, 2009 Male patient from UNITED STATES , weighting 177.3 lb, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, fluid overload, pleural effusion. Dacarbazine dosage: 1000mg/m2 Q 3 Wk. During the same period patient was treated with DASATINIB (100mg Qd Day 2-19) (View Dasatinib Review and Dasatinib Label ), METAPROLOL (View Metaprolol Review and Metaprolol Label ), ZOCOR (View Zocor Review and Zocor Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), CALCIUM (View Calcium Review and Calcium Label ), GLUCOSAMINE (View Glucosamine Review and Glucosamine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6370638-3 | Haemothorax, Pleural Effusion
Patient was taking Dacarbazine (View Usage). Patient had the following side effects: haemothorax, pleural effusion on Sep 21, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 177.3 lb, was diagnosed with malignant melanoma and. Dacarbazine dosage: 1000mg/m2 Q 3 Wk. During the same period patient was treated with DASATINIB (100mg Qd Day 2-19) (View Dasatinib Review and Dasatinib Label ), METAPROLOL (View Metaprolol Review and Metaprolol Label ), ZOCOR (View Zocor Review and Zocor Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), CALCIUM (View Calcium Review and Calcium Label ), GLUCOSAMINE (View Glucosamine Review and Glucosamine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), VITAMINS (View Vitamins Review and Vitamins Label ). Patient was hospitalized.

6306887-X | Ascites, Blood Bilirubin Increased, Blood Creatine Increased, Blood Sodium Decreased, Haemodialysis, Haemoglobin Decreased, Oedema Peripheral, Oliguria
Adverse event was reported on Jul 31, 2009 by a Male patient taking Dacarbazine (View Usage) (Dosage: 250 Mg/m^2 On Days 1-3 Of Treatment) was diagnosed with metastatic malignant melanoma and. Location: UNITED KINGDOM , 41 years of age, After Dacarbazine was administered, patient had the following side effects: ascites, blood bilirubin increased, blood creatine increased, blood sodium decreased, haemodialysis, haemoglobin decreased, oedema peripheral, oliguria. During the same period patient was treated with CISPLATIN (30 Mg/m^2 On Days 1-3 Of Treatment) (View Cisplatin Review and Cisplatin Label ), INTERFERON ALFA (10 Mu/m2 On Days 1-5 Of Treatment) (View Interferon Alfa Review and Interferon Alfa Label ).

6302993-4 | Abdominal Pain, Hypotension
on Jul 27, 2009 Female patient from UNITED STATES , 62 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), hypotension. Dacarbazine dosage: As Used: 1300 Mg. During the same period patient was treated with IPILIMUMAB (As Used: 569 Mg) (View Ipilimumab Review and Ipilimumab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CELEXA (View Celexa Review and Celexa Label ), SIMVASTIN (View Simvastin Review and Simvastin Label ), MULTIPLE VITAMINS (View Multiple Vitamins Review and Multiple Vitamins Label ), BUDESONIDE (View Budesonide Review and Budesonide Label ), PROCTOFOAM HC (View Proctofoam Hc Review and Proctofoam Hc Label ). Patient was hospitalized.

6290840-9 | Anaemia, Lower Gastrointestinal Haemorrhage, Thrombocytopenia
on Jul 29, 2009 Male patient from UNITED STATES , 40 years of age, weighting 195.3 lb, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient had the following side effects: anaemia, lower gastrointestinal haemorrhage, thrombocytopenia. Dacarbazine dosage: 1000 Mg/m2 Q22 Days. During the same period patient was treated with DASATINIB (100 Mg Qd X18 Days) (View Dasatinib Review and Dasatinib Label ). Patient was hospitalized.

6274936-3 | Body Temperature Increased, Haematocrit Decreased, Haemoglobin Decreased, Lung Infiltration, Lymphocyte Count Abnormal, Platelet Count Decreased, Red Blood Cell Count Decreased, White Blood Cell Count Decreased
Patient was taking Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: body temperature increased, haematocrit decreased, haemoglobin decreased, lung infiltration, lymphocyte count abnormal, platelet count decreased, red blood cell count decreased, white blood cell count decreased on Jul 01, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 24 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Dacarbazine dosage: . During the same period patient was treated with BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ). Patient was hospitalized.

6271572-X | Paraesthesia
Adverse event was reported on Jun 30, 2008 by a Male patient taking Dacarbazine (View Usage) (Dosage: Sometime In June 2008) was diagnosed with malignant melanoma and. Location: UNITED STATES , 67 years of age, Patient experienced the following unwanted or unexpected effects: paraesthesia.

6271571-8 | Gastritis
on Mar 02, 2009 Female patient from UNITED STATES , weighting 132.3 lb, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). Patient had the following side effects: gastritis. Dacarbazine dosage: Iv. Patient was hospitalized.

6264288-7 | Abdominal Pain, Hypotension
on Jun 29, 2009 Female patient from UNITED STATES , 62 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), hypotension. Dacarbazine dosage: As Used: 1300 Mg. During the same period patient was treated with IPILIMUMAB (As Used: 569 Mg) (View Ipilimumab Review and Ipilimumab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CELEXA (View Celexa Review and Celexa Label ), SIMVASTIN (View Simvastin Review and Simvastin Label ), MULTIPLE VITAMINS (View Multiple Vitamins Review and Multiple Vitamins Label ), BUDESONIDE (View Budesonide Review and Budesonide Label ), PROCTOFOAM HC (View Proctofoam Hc Review and Proctofoam Hc Label ). Patient was hospitalized.

6258488-X | Acute Myeloid Leukaemia, Leukaemia Recurrent
Patient was taking Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, leukaemia recurrent on Jun 23, 2009 from UNITED STATES Additional patient health information: Female patient , 68 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Dacarbazine dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), (VINBLASTINE) (View (vinblastine) Review and (vinblastine) Label ), (THERAPEUTIC RADIOPHARMACEUTICALS) (View (therapeutic Radiopharmaceuticals) Review and (therapeutic Radiopharmaceuticals) Label ).

6258488-X | Acute Myeloid Leukaemia, Leukaemia Recurrent
Adverse event was reported on Jun 23, 2009 by a Female patient taking Dacarbazine (View Usage) (Dosage: ) was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Location: UNITED STATES , 68 years of age, Patient had the following side effects: acute myeloid leukaemia, leukaemia recurrent. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), (VINBLASTINE) (View (vinblastine) Review and (vinblastine) Label ), (THERAPEUTIC RADIOPHARMACEUTICALS) (View (therapeutic Radiopharmaceuticals) Review and (therapeutic Radiopharmaceuticals) Label ).

6236916-3 | Abdominal Pain, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased
on Jun 15, 2009 Male patient from UNITED STATES , 79 years of age, was diagnosed with malignant melanoma and was treated with Dacarbazine (View Usage). After Dacarbazine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), alanine aminotransferase increased, aspartate aminotransferase increased. Dacarbazine dosage: Cyclical. During the same period patient was treated with IPILIMUMAB (Cyclical) (View Ipilimumab Review and Ipilimumab Label ), HYZAAR HCTZ (View Hyzaar Hctz Review and Hyzaar Hctz Label ), SPIRIVA (View Spiriva Review and Spiriva Label ), PEPCID AC (View Pepcid Ac Review and Pepcid Ac Label ), BENADRYL (View Benadryl Review and Benadryl Label ), TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ). Patient was hospitalized.

6218666-2 | Renal Failure Acute
on May 28, 2009 Male patient from UNITED STATES , 77 years of age, weighting 154.3 lb, was diagnosed with metastatic malignant melanoma, pain (What is pain?) and was treated with Dacarbazine (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute. Dacarbazine dosage: X 2 Cycles. During the same period patient was treated with IMC 1121B (X 2 Cycles) (View Imc - 1121b Review and Imc - 1121b Label ), IMC 1121B (View Imc - 1121b Review and Imc - 1121b Label ), MORPHINE (Total Daily Dose: 120 Mg) (View Morphine Review and Morphine Label ), PEGFILGRASTIM (Total Daily Dose: 6 Mg) (View Pegfilgrastim Review and Pegfilgrastim Label ), PROCHLORPERAZINE (As Used: 10 Mg) (View Prochlorperazine Review and Prochlorperazine Label ), METHYLPHENIDATE HCL (Total Daily Dose: 10 Mg) (View Methylphenidate Hcl Review and Methylphenidate Hcl Label ), NEXIUM (Total Daily Dose: 40 Mg) (View Nexium Review and Nexium Label ). Patient was hospitalized.

6218663-7 | Cardiac Arrest
Patient was taking Dacarbazine (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?) on Jun 03, 2009 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 392.4 lb, was diagnosed with metastatic malignant melanoma, mineral supplementation, hypertension, hypersensitivity, nausea (What is nausea?) and. Dacarbazine dosage: . During the same period patient was treated with IMC 1121B (View Imc-1121b Review and Imc-1121b Label ), POTASSIUM CHLORIDE (Total Daily Dose: 240 Meq) (View Potassium Chloride Review and Potassium Chloride Label ), TEKTURNA (Total Daily Dose: 300 Mg) (View Tekturna Review and Tekturna Label ), BACTROBAN (View Bactroban Review and Bactroban Label ), BYSTOLIC (Total Daily Dose: 10 Mg) (View Bystolic Review and Bystolic Label ), CENTRUM SILVER (1 Daily) (View Centrum Silver Review and Centrum Silver Label ), CLARITIN (Total Daily Dose: 10 Mg) (View Claritin Review and Claritin Label ), COMPAZINE (Every 6 Hours As Needed) (View Compazine Review and Compazine Label ).